Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05965700 · ClinicalTrials.gov registry record · Phase 1

NVG-291 in Spinal Cord Injury Subjects

A Phase 1 study of Spinal Cord Injuries and Chronic Spinal Cord Injury, sponsored by NervGen Pharma.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT05965700: Recruiting Phase 1 study of Spinal Cord Injuries and Chronic Spinal Cord Injury, sponsored by NervGen Pharma.

NCT05965700 is a Phase 1 study of Spinal Cord Injuries and Chronic Spinal Cord Injury that is actively recruiting participants, run by NervGen Pharma. The registered enrollment target is 40 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05965700, a Phase 1 study of Spinal Cord Injuries and Chronic Spinal Cord Injury, is actively recruiting participants, sponsored by NervGen Pharma.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

Primary Outcome

MEP amplitudes (corticospinal contribution) in key target muscle groups

Conditions Studied

Spinal Cord Injuries Chronic Spinal Cord Injury Subacute Spinal Cord Injury

Interventions

  • DRUG NVG-291

Study Locations (1)

Illinois

  • Shirley Ryan AbilityLab - Chicago

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-08-08
Est. Completion 2026-04
Phase Phase 1
NervGen Pharma

1 total trials

What NCT05965700 shows while recruiting

NCT05965700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (34% lower).

The record links to 3 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which NVG-291 is the first listed.

NCT05965700 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05965700 about?

NCT05965700 is a clinical study titled "NVG-291 in Spinal Cord Injury Subjects". A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

What is the current status of trial NCT05965700?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-08. Estimated completion is 2026-04.

What conditions does trial NCT05965700 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury.

What interventions are being tested in trial NCT05965700?

The interventions under investigation include: NVG-291 (DRUG).

Who is sponsoring clinical trial NCT05965700?

This trial is sponsored by NervGen Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05965700 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05965700's enrollment target sits among peer trials

40 72nd of 202 higher than 124 of 202 other Spinal Cord Injuries trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spinal Cord Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

More recruiting context for NCT05965700

Source: ClinicalTrials.gov NCT05965700, the US trial registry maintained by the National Library of Medicine. NCT05965700 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.